$21.12
Value $7.4B
AMRX and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$21.12
Value $7.4B
$278.70
Value $672B
Amneal Pharmaceuticals (AMRX) has a market value of $7.4B and Johnson & Johnson (JNJ) $672B. Over the last year, with dividends, AMRX moved +81.4% and JNJ +45.4%. The P/E is 55.2 for AMRX and 41.7 for JNJ. Dividend yield: AMRX none, JNJ 1.89%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
AMRX$7.4B
JNJ$672B
JNJ is 91 times AMRX
Revenue, 12 months
AMRX$3.2B
JNJ$99.3B
JNJ is 31 times AMRX
Net income, 12 months
AMRX$133M
JNJ$16.1B
JNJ is 121 times AMRX
Operating margin
AMRX15.0%
JNJ–
ROIC
AMRX16.7%
JNJ12.4%
4.3 points apart
P/E
AMRX55.2
JNJ41.7
AMRX is 1.3 times JNJ
Dividend yield
AMRX0.0%
JNJ1.9%
1.9 points apart
5-year return
AMRX+326.7%
JNJ+97.0%
229.7 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
AMRX+326.7%
JNJ+96.9%
| Period | AMRXWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +81.4%Price +81.4% | +45.4%Price +42.2% |
| 3 years since November 17, 2023 | +366.2%+67.1% a yearPrice +366.2% | +102.6%+26.5% a yearPrice +86.1% |
| 5 years since November 16, 2021 | +326.7%+33.7% a yearPrice +326.7% | +97.0%+14.5% a yearPrice +71.3% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
AMRXAmneal PharmaceuticalsJNJJohnson & Johnson
| Price | $21.12 | $278.70 |
|---|---|---|
| Market value | $7.4B | $672B |
| Enterprise value (EV) | $10.2B | $699B |
| P/E | 55.2 | 41.7 |
| P/E, 5-year median | – | 21.9 |
| P/B | 13.9 | 8.2 |
| EV/EBIT | 21.3 | 39.4 |
| Free cash flow yield | 1.2% | 3.1% |
| Revenue, 12 months | $3.2B | $99.3B |
|---|---|---|
| Net income, 12 months | $133M | $16.1B |
| Free cash flow, 12 months | $88M | $20.6B |
| Earnings per share, 12 months | $0.42 | $6.59 |
| Revenue growth, year on year | 8.1% | 6.1% |
| Revenue growth a year, past | +8.7%over 5 years | +2.7%over 5 years |
| EPS growth a year, past | -18.5%over 5 years | +14.9%over 5 years |
| Gross margin | 40.2% | 67.6% |
|---|---|---|
| Operating margin | 15.0% | – |
| Net margin | 4.2% | 16.2% |
| ROIC | 16.7% | 12.4% |
| ROE | 196.8% | 19.7% |
| Cash | $157M | $17.2B |
|---|---|---|
| Total debt | $3.0B | $44.7B |
| Net debt / EBITDA | 5.3 | 1.1 |
| Interest cover | – | 18.0× |
| Dividend yield | – | 1.9% |
|---|---|---|
| Dividend per share, 12 months | – | $5.28 |
| Dividend growth a year, past | – | +5.3%over 5 years |
| Buyback yield | – | 0.9% |
| Shareholder yield | – | 2.8% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($672B) is about 91.3 times Amneal Pharmaceuticals ($7.4B), at today's prices.
Since November 16, 2021, AMRX's price moved +326.7% and JNJ's +71.3%. With dividends: AMRX +326.7% (+33.7% a year), JNJ +97.0% (+14.5% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Amneal Pharmaceuticals and 1.89% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.
At today's price, the P/E is 55.2 for AMRX and 41.7 for JNJ. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 4.2% for Amneal Pharmaceuticals and 16.2% for Johnson & Johnson, and the operating margin 15.0% and –. Revenue was $3.2B and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.